Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes that its partner company Polarean Imaging plc (“Polarean”) has announced that the first patient has been enrolled in its Phase III FDA clinical trial which aims to demonstrate non-inferiority of the Company’s drug-device combination, using hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved comparator.
Polarean Update
London and New York, 23 August 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes that its partner company Polarean Imaging plc (“Polarean”) has announced that the first patient has been enrolled in its Phase III FDA clinical trial which aims to demonstrate non-inferiority of the Company’s drug-device combination, using hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved comparator.
This news means that Polarean is now in the process of its Phase III clinical trial. Polarean is listed on the AIM market of the London Stock Exchange under the ticker POLX.
Amphion currently holds c. 17 million shares, equivalent to 21.7% of the enlarged Share Capital of Polarean.
For further information please contact:
Amphion Innovations
Tel: +1 (212) 210 6224
Charlie Morgan
